Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats : clinical and laboratory evaluation
Autor: | David McGahie, Nuno Sepúlveda, Luís Tavares, Maria M. R. E. Niza, Solange Gil, Ana Duarte, Rodolfo Oliveira Leal |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2014 |
Předmět: |
Feline immunodeficiency virus
Feline Immunodeficiency Virus (FIV) viruses Administration Oral Immunodeficiency Virus Feline Real-Time Polymerase Chain Reaction Recombinant-Feline Interferon Omega (rFeIFN-ω) Article Statistics Nonparametric law.invention Feces law Feline Acquired Immunodeficiency Syndrome medicine Animals Immunologic Factors CATS General Veterinary biology Oral therapy business.industry Acute-phase protein biology.organism_classification Recombinant Proteins Immune-modulation 3. Good health Real-time polymerase chain reaction Interferon Type I Immunology Cats Recombinant DNA RNA Viral business Interferon type I Acute-Phase Proteins medicine.drug |
Zdroj: | Repositório Científico de Acesso Aberto de Portugal Repositório Científico de Acesso Aberto de Portugal (RCAAP) instacron:RCAAP Research in Veterinary Science |
Popis: | Articles in International Journals Recombinant-Feline Interferon-Omega (rFeIFN-ω) is an immune-modulator licensed for use subcutaneously in Feline Immunodeficiency virus (FIV) therapy. Despite oral protocols have been suggested, little is known about such use in FIV-infected cats. This study aimed to evaluate the clinical improvement, laboratory findings, concurrent viral excretion and acute phase proteins (APPs) in naturally FIV-infected cats under oral rFeIFN-ω therapy (0.1 MU/cat rFeIFN-ω PO, SID, 90 days). 11 FIV-positive cats were treated with oral rFeIFN-ω (PO Group). Results were compared to previous data from 7 FIV-positive cats treated with the subcutaneous licensed protocol (SC Group). Initial clinical scores were similar in both groups. Independently of the protocol, rFeIFN-ω induced a significant clinical improvement of treated cats. Concurrent viral excretion and APP’s variation were not significant in the PO Group. Oral rFeIFN-ω can be an effective alternative therapy for FIV-infected cats, being also an option for treatment follow-up in cats submitted to the licensed protocol. |
Databáze: | OpenAIRE |
Externí odkaz: |